CNBC Investing Club: Cramer’s Morning Take on Apple 3/19/26

SPEAKER_1 (0:00)

Trading at Schwab is powered by Ameritrade, giving you even more specialized support than ever before, like access to the trade desk. Our team of passionate traders ready to tackle anything from the most complex trading questions to a simple strategy gut check. Need assistance? No problem. Get 24-7 professional answers and live help and access support by phone, email, and in-platform chat. That's how Schwab is here for you, to help you trade brilliantly. Learn more at schwab.com/trading.

SPEAKER_2 (0:28)

At Strayer University, we help students like you go from will I to why not. For over 130 years, we've been innovating higher education to make it more affordable, accessible, and attainable so you can reach your goals. Go from thinking can I to yes I can and keep striving. Visit strayer.edu to learn more. Strayer University is certified to operate in Virginia by Schwab and as many campuses, including at 2121 15th Street North in Arlington, Virginia.

Jim Cramer (1:00)

Jim Cramer here to share a short preview of my take on the market from today's members only CNBC Investing Club morning meeting. Join the club for full access to the morning meeting every day at 1020 AM. Visit cnbc.com/morningtake to sign up today. That's one word, morning take.

Everyone had agreed that they weren't going to bomb any of these fields. Initially the press said that the United States had bombed Par. Then it turned out that Israel bombed Par. And then of course the Iranians easily, even though everyone says they've been degraded, easily attacked these facilities at Qatar, knockout 17%. And then does Israel retaliate or is it over? If it's over, then you're going to see oil go down and all our stocks are going to go up. And a stock like Boeing, which is in free fall, goes higher. And so I do believe we have to do some buying. Now, we don't know Micron. No, geez, that's ridiculous, we know that. We don't know Micron, but Micron is a company that when it opens down, it tends to rally. There was nothing they get about Micron. The numbers, when it goes down to four times earnings, that is typically where you expect that the numbers can roll over, but they're not. Because Micron is a creature of how much SK Hynex and Samsung are building, and they're not. They're not building enough. Therefore, the prices aren't done going up. They are the ones, you want demand destruction, you got to be careful. Unless you find that Dell is able to mitigate the pricing, Dell being the most important company in this whole food chain, I would be worried. But I think Dell will mitigate pricing. I said that after talking to Michael Dell. So I'm not sweating the program of companies who are buyers, but I do think it's a great opportunity when it was down 25

SPEAKER_4 (2:47)

It is interesting to see off the decline in Micron today. You mentioned Dell's higher. Cisco called out memory prices on their earnings call. Apple did as well. And last I checked, yes, they're all positive today in the down tape. Apple, by the way, had some news. This was Reuters reporting that Apple's smartphone sales in China increased 23% year over year to start 2026

Jim Cramer (3:14)

Exactly the opposite of what everyone was saying.

SPEAKER_4 (3:16)

Gaining share in a region where total smartphone shares fell 4% in the period. So maybe this is a sign that they are better managing memory costs versus competitors that have to raise price.

Jim Cramer (3:28)

I thought Apple should be a buyer. Now, people should understand it's really important.

There is no increase in... He's not... He's not making more DRAM. That was the whole point of the conversation. He told me, he said, listen, we have to make high bandwidth memory. We're not increasing DRAM. So people were buying the companies thinking that DRAM is going to go down. I mean, please read the Comiscoil. That's just not true.

SPEAKER_5 (3:49)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_6 (4:21)

Snoring, gasping during sleep, feeling fatigued? Wake up to ZepBound Terzepotide. The first and only FDA approved prescription medicine for moderate to severe obstructive sleep apnea, OSA and adults with obesity. ZepBound is an injectable prescription medicine that may help adults with moderate to severe obstructive sleep apnea, OSA and obesity to improve their OSA. ZepBound should be used with a reduced calorie diet and increased physical activity. ZepBound is approved as a 2.5, 5, 7.5, 10, 12.5 or 15 milligram injection.